TGTX - TG Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5703.07M
Enterprise Value 3605.58M
Trailing P/E N/A
Forward P/E 1-5.82
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)4,625.43
Price/Book (mrq)33.36
Enterprise Value/Revenue 33,984.06
Enterprise Value/EBITDA 6-3.62

Trading Information

Stock Price History

Beta (3Y Monthly) 2.14
52-Week Change 3-33.58%
S&P500 52-Week Change 36.70%
52 Week High 312.90
52 Week Low 33.32
50-Day Moving Average 37.66
200-Day Moving Average 36.68

Share Statistics

Avg Vol (3 month) 31.52M
Avg Vol (10 day) 3889.87k
Shares Outstanding 590.84M
Float 55.67M
% Held by Insiders 111.16%
% Held by Institutions 168.87%
Shares Short (Jun 28, 2019) 414.43M
Short Ratio (Jun 28, 2019) 48.76
Short % of Float (Jun 28, 2019) 422.18%
Short % of Shares Outstanding (Jun 28, 2019) 415.88%
Shares Short (prior month May 31, 2019) 413.55M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 25625/100
Last Split Date 3Apr 30, 2012

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-110,205.26%

Management Effectiveness

Return on Assets (ttm)-87.78%
Return on Equity (ttm)-319.87%

Income Statement

Revenue (ttm)152k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)0.00%
Gross Profit (ttm)152k
EBITDA -167.42M
Net Income Avi to Common (ttm)-167.11M
Diluted EPS (ttm)-2.14
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)92.47M
Total Cash Per Share (mrq)1.08
Total Debt (mrq)37.86M
Total Debt/Equity (mrq)196.65
Current Ratio (mrq)1.72
Book Value Per Share (mrq)0.23

Cash Flow Statement

Operating Cash Flow (ttm)-134.23M
Levered Free Cash Flow (ttm)-71.45M